Cardiovascular and metabolic disease segment
AstraZeneca’s (AZN) Cardiovascular and Metabolic Diseases (or CVMD) segment includes various products like Brilinta, Byetta, Farxiga, Bydureon, Onglyza, Symlin, and legacy products like Atacand, Crestor, Seloken, and others. The CVMD segment reported revenues of $1.8 billion during 3Q17, a 4% decline in operating revenues driven by lower sales of Bydureon, Crestor, Onglyza, and Seloken. However, the increased sales of Atacand, Brilinta, and Farxiga substantially offset the decline in revenues during 3Q17.
The above chart compares the revenues for key CVMD products over the last few quarters.
Brilinta, a cardiovascular drug, reported revenues of $284 million during 3Q17, a 36% increase in operating revenues. Brilinta revenues also reported a 1% positive impact of foreign exchange during 3Q17. The US sales rose 67% to $140 million, while the sales from European markets rose 12% to $78 million during 3Q17. The sales from emerging markets rose 20% to $54 million during 3Q17.
Crestor reported revenues of $580 million during 3Q17, a 14% decrease in operating revenues. The decline in revenues was due to lower US sales and lower sales from European markets, partially offset by increased sales from emerging markets.
Farxiga reported revenues of $285 million during 3Q17, a 29% increase in operating revenues. Farxiga revenues also reported a 1% positive impact of foreign exchange during 3Q17. The growth was driven by increased sales across all the markets.
Atacand reported revenues of $80 million during 3Q17, an 11% increase in operating revenues.
Other CVMD products
Other products in this segment include Bydureon, Byetta, Onglyza, and Seloken. These drugs reported lower sales across all the regions except emerging markets.
The Vanguard International High Dividend Yield ETF (VYMI) holds 6.9% of its total investments in healthcare companies. VYMI holds 0.8% in AstraZeneca (AZN), 0.8% in GlaxoSmithKline (GSK), 1.0% in Sanofi (SNY), and 2.0% in Novartis AG (NVS).